Agios Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is...
Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03397329
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
- Conditions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03361358
- Locations
- 🇺🇸
Boston, MA, Boston, Massachusetts, United States
🇺🇸Nashville, TN, Nashville, Tennessee, United States
🇪🇸Barcelona, Spain, Barcelona, Spain
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03282513
- Locations
- 🇺🇸
DaVita Clinical Research- Minnesota, Minneapolis, Minnesota, United States
🇺🇸DaVita Clinical Research- Colorado, Lakewood, Colorado, United States
Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03250598
- Locations
- 🇺🇸
West Coast Clinical Trial (WCCT) Global, Inc., Cypress, California, United States
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Registration Number
- NCT03245424
Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03071770
- Locations
- 🇺🇸
West Coast Clinical Trial (WCCT), Cypress, California, United States
Drug-Drug Interaction Study of AG120 in Healthy Subjects
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02831972
A Safety and Tolerability Study of AG-519 in Healthy Subjects
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02630927
- Locations
- 🇬🇧
Quotient Clinical, Ruddington Fields, Nottingham, United Kingdom
Food Effect Study of AG120 in Healthy Subjects
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02579707
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02492737